Acotec Scientific Holdings Limited
0.64
EUR
-0.04
(-6.57%)
Acotec Scientific Holdings Limited
GETTEX:7W3
(Gettex)
Recent
price
0.64
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Acotec Scientific Holdings Limited, a China-based interventional medical device company listed on the Hong Kong Stock Exchange (6669.HK), develops and commercializes innovative treatment solutions for vascular diseases leveraging four core technology platforms including drug-coating, radiofrequency ablation, polymer materials and aspiration technologies; its product portfolio spans vascular surgery, cardiology, nephrology and neurology with over 30 pipelines and 22 commercialized devices such as paclitaxel drug-coated balloons (DCBs) AcoArt Orchid & Dhalia for superficial femoral and popliteal artery disease, AcoArt Tulip & Litos for below-the-knee arteries, PTA balloons AcoArt Iris & Jasmin and AcoArt Lily & Rosmarin, peripheral aspiration systems AcoStream and 2nd Generation AcoStream for deep vein thrombosis, radiofrequency ablation system AcoArt Cedar for varicose veins, peripheral support catheter Vericor, PTA balloon P-Conic, introducer sheath set Acotrace, delivery catheter for aspiration catheter, semi-compliant PTCA balloon YAN, coronary CTO recanalization balloon RT-Zero, coronary CTO micro-catheters Vericor-14, Vericor-RS and Vericor-S2, coronary high-pressure balloon YIYAN, cardiac valve balloon dilation catheter RunFlow, paclitaxel-eluting coronary DCB AcoArt Camellia, AV scoring balloon Peridge and intracranial PTA balloon Neo-Skater. Founded in 2011 and headquartered at 4-5/F, Building 1, No. 16 Hongda North Road, Beijing Economic-Technological Development Area, China, the company operates primarily in Mainland China with international expansion into Europe, Latin America, Asia and other regions including Germany, Italy, Brazil and Turkey; it functions as a subsidiary of Boston Scientific Group plc following the latter's majority stake acquisition in February 2023. In 2024, Acotec achieved NMPA approvals for seven new products including Acotrace, Delivery Catheter for Aspiration Catheter, YIYAN high-pressure balloon, Vericor-RS, RunFlow, AcoArt Camellia and Peridge, launched a record seven products boosting hospital adoptions beyond 2,000, reported revenue of RMB534 million up 12.7% year-on-year with venous intervention and other products contributing 40%, advanced FDA IDE-approved clinical trials for AcoArt Litos in the US and Europe, progressed overseas registrations for core DCBs in markets like Chile, Austria and Poland, and deepened collaboration with Boston Scientific under 2023 framework agreements encompassing product commercialization in Hong Kong, Taiwan and China, manufacturing services and joint R&D for new devices.